Evidence map›Paper›PMID 39995757›Full record

ArticleBeilstein journal of nanotechnology2025

Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide.

Radmila Milenkovska, Nikola Geskovski, Dushko Shalabalija, Ljubica Mihailova, Petre Makreski, Dushko Lukarski, Igor Stojkovski, Maja Simonoska Crcarevska, Kristina Mladenovska

Abstract read
In one paragraph

Article in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nanomaterials for biomedical applications.Beilstein journal of nanotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Radmila MilenkovskaInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0009-0004-8227-4298
Nikola GeskovskiInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0002-2073-5632
Dushko ShalabalijaInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0003-2271-9529
Ljubica MihailovaInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0003-0328-6780
Petre MakreskiInstitute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, Str. Arhimedova No. 5, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0003-0662-5995
Dushko LukarskiUniversity Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 17, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0003-4286-2330
Igor StojkovskiUniversity Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 17, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0002-5770-2578
Maja Simonoska CrcarevskaInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0002-1927-7101
Kristina MladenovskaInstitute of Pharmaceutical Technology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Blv. Mother Theresa No. 45, 1000 Skopje, Republic of North Macedonia.ORCID https://orcid.org/0000-0003-2503-4699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, temozolomide (TMZ), a drug used for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM), was incorporated into multiwalled carbon nanotubes (MWCNTs) and a MWCNTs-graphene (MWCNTs-G) hybrid compound, covalently functionalized with polyethylene glycol (PEG) 6000 and folic acid (FA), with an aim to prepare nanocarriers with the potential to prolong the drug circulation time, cross the blood-brain-tumor barrier (BBTB), and provide targeted and controlled drug release in the brain tumor cells. Cytotoxicity and effects on cell membrane integrity of the blank and TMZ-loaded dual-functionalized carbon nanostructures (CNs) were evaluated in vitro on a GBM cell line (U87MG), as well as their radiosensitizing properties after exposure of the pre-treated GBM cells to gamma radiation with a standard clinical dose for patients with GBM. All prepared formulations underwent biopharmaceutical and physicochemical characterization, including the formulations exposed to irradiation under the same conditions. For physicochemical characterization of the formulations, different techniques were used by which successful functionalization of the CNs and TMZ loading were confirmed and visualized; no significant changes in the structure of the CNs and TMZ after irradiation were observed. With single and dual functionalization, formulations with relatively high TMZ loading efficiency and drug content were prepared. They exhibited homogeneous particle size distributions and mean particle sizes and surface charges suitable for crossing the BBTB and targeting brain cancer cells. A biphasic drug release profile was observed for all functionalized TMZ-loaded formulations in simulated in vivo conditions, with a sustained release pointing to the potential for controlled release of TMZ in brain tumor cells. The formulations of the hybrid CN MWCNTs-G compared to the corresponding MWCNTs were characterized by a similar or slightly higher TMZ content, larger particle size, similar surface charge, and slightly faster TMZ release, which can be attributed to the planar structure of graphene that promotes TMZ binding to the surface on a larger scale. For the irradiated CNs, lower values for particle size, more positive values for surface charge, and accelerated TMZ release were observed, which could be explained by changes in the physicochemical characteristics of the prepared formulations upon irradiation. Significant concentration-dependent toxicity was observed for blank dual-functionalized CNs, being higher for MWCNTs-G-PEG6000-FA compared to MWCNTs-PEG6000-FA at the same formulation concentrations. With incorporation of TMZ into the functionalized CNs, the cell viability additionally decreased, maintaining the trend for higher cytotoxicity of the hybrid CN. Additional decrease in the viability of cells was observed when GBM cells pre-treated with the corresponding CNs were exposed to irradiation, which could be ascribed to changes in size, surface charge, and release kinetics of TMZ and to irradiation-induced changes in the microenvironment and cell membranes that promote uptake of a larger volume of carriers in the GBM cells. The higher cytotoxicity observed in the hybrid carrier formulations could most likely be attributed to the length of the hybrid carrier and the higher proportion of planar surface, which promotes more intense contact with the cells and rupture of cell membranes. Overall, the findings demonstrate the radiosensitizing properties of not only TMZ but also of CNs and point to a clinical benefit from combined treatment with carbon nanocarriers of TMZ and radiotherapy in GBM.

Indexed as

carbon nanostructurescytotoxicityglioblastoma multiformeradiosensitizing propertiestemozolomide

Identifiers

PMID39995757
PMCPMC11849551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.